Summary
9.56 -0.21(-2.15%)11/06/2024
Haleon plc (HLN)
Haleon plc (HLN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.15 | -3.35 | -1.46 | -1.64 | -7.66 | 2.15 | 0.00 | -19.48 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 9.56 | |
| Open | 9.57 | |
| High | 9.58 | |
| Low | 9.49 | |
| Volume | 4,999,359 | |
| Change | -0.21 | |
| Change % | -2.15 | |
| Avg Volume (20 Days) | 4,547,769 | |
| Volume/Avg Volume (20 Days) Ratio | 1.10 | |
| 52 Week Range | 7.49 - 9.05 | |
| Price vs 52 Week High | 5.64% | |
| Price vs 52 Week Low | 27.64% | |
| Range | -0.49 | |
| Gap Up/Down | -0.09 | |
Fundamentals | ||
| Market Capitalization (Mln) | 48,263 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
11/04 09:00 EST - globenewswire.com
Haleon Selects Vistar Media as Preferred Global Partner for Programmatic Out-of-Home (OOH) Advertising
Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy
Haleon Selects Vistar Media as Preferred Global Partner for Programmatic Out-of-Home (OOH) Advertising
Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy
11/02 10:09 EST - seekingalpha.com
Haleon plc (HLN) Q3 2024 Sales Call Transcript
Haleon plc (NYSE:HLN ) Q3 2024 Sales Conference Call October 31, 2024 5:00 AM ET Company Participants Rakesh Patel - Director of Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Group AG David Hayes - Jefferies Group LLC Iain Simpson - Barclays Rashad Kawan - Morgan Stanley Celine Pannuti - JPMorgan Chase & Co. Victoria Petrova - BofA Securities Karel Zoete - Kepler Cheuvreux Tom Sykes - Deutsche Bank Rakesh Patel Good morning everyone, and welcome to Haleon's Conference Call for our Third Quarter Trading Statement. I am Rakesh Patel, Director, Investor Relations, and with me today is Tobias Hestler, our CFO.
Haleon plc (HLN) Q3 2024 Sales Call Transcript
Haleon plc (NYSE:HLN ) Q3 2024 Sales Conference Call October 31, 2024 5:00 AM ET Company Participants Rakesh Patel - Director of Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Group AG David Hayes - Jefferies Group LLC Iain Simpson - Barclays Rashad Kawan - Morgan Stanley Celine Pannuti - JPMorgan Chase & Co. Victoria Petrova - BofA Securities Karel Zoete - Kepler Cheuvreux Tom Sykes - Deutsche Bank Rakesh Patel Good morning everyone, and welcome to Haleon's Conference Call for our Third Quarter Trading Statement. I am Rakesh Patel, Director, Investor Relations, and with me today is Tobias Hestler, our CFO.
10/31 03:58 EST - proactiveinvestors.co.uk
Panadol maker Haleon takes hit from currency headwinds
Currency fluctuations meant Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100-listed Panadol and Sensodyne owner, saw year-on-year reported revenue by 0.6% to £2.78 billion in the third quarter. Stripping away the impact of the weaker US dollar, the consumer health giant's organic revenues increased by 6.1%.
Panadol maker Haleon takes hit from currency headwinds
Currency fluctuations meant Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100-listed Panadol and Sensodyne owner, saw year-on-year reported revenue by 0.6% to £2.78 billion in the third quarter. Stripping away the impact of the weaker US dollar, the consumer health giant's organic revenues increased by 6.1%.
10/31 03:21 EST - reuters.com
Haleon reports marginal decline in third-quarter revenue
Haleon reported a marginal fall in its third-quarter revenue on Thursday, hurt by declines in its pain relief and digestive health segments.
Haleon reports marginal decline in third-quarter revenue
Haleon reported a marginal fall in its third-quarter revenue on Thursday, hurt by declines in its pain relief and digestive health segments.
10/09 08:11 EST - proactiveinvestors.co.uk
Haleon gets target hike as UBS raises 'forever' sales target
Haleon PLC (LSE:HLN, NYSE:HLN) has received a price target upgrade from UBS ahead of its third quarter update on 31 October as it becomes increasingly confident over its longer-term revenue opportunities. Foreign exchange movements will affect this year's adjusted earnings, which UBS has trimmed by 3%, but that aside the Swiss bank believes the GSK spin-iut has shown it can deliver 4-6% organic sales growth.
Haleon gets target hike as UBS raises 'forever' sales target
Haleon PLC (LSE:HLN, NYSE:HLN) has received a price target upgrade from UBS ahead of its third quarter update on 31 October as it becomes increasingly confident over its longer-term revenue opportunities. Foreign exchange movements will affect this year's adjusted earnings, which UBS has trimmed by 3%, but that aside the Swiss bank believes the GSK spin-iut has shown it can deliver 4-6% organic sales growth.
10/07 02:25 EST - proactiveinvestors.co.uk
Futura Medical in line for $5m milestone payment as Haleon's US Eroxon launch gets underway
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has secured a $5 million milestone payment following the US launch of its flagship product, Eroxon. The payment was triggered as Haleon, the company's distribution partner, began fulfilling online pre-orders and making fast-acting erectile dysfunction gel available in American retail stores.
Futura Medical in line for $5m milestone payment as Haleon's US Eroxon launch gets underway
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has secured a $5 million milestone payment following the US launch of its flagship product, Eroxon. The payment was triggered as Haleon, the company's distribution partner, began fulfilling online pre-orders and making fast-acting erectile dysfunction gel available in American retail stores.
10/03 12:46 EST - zacks.com
HLN or PODD: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Insulet (PODD). But which of these two stocks is more attractive to value investors?
HLN or PODD: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Insulet (PODD). But which of these two stocks is more attractive to value investors?
10/01 07:35 EST - proactiveinvestors.co.uk
Haleon's buy rating restated after Pfizer cuts down stake
UBS has reiterated its buy rating on Haleon PLC (LSE:HLN, NYSE:HLN) shares after news that former parent company Pfizer Inc (NYSE:PFE, ETR:PFE) further pared down its stake in the FTSE 100-listed Sensodyne and Panadol maker. Haleon, which comprises the former consumer divisions of Pfizer and GSK PLC (LSE:GSK, NYSE:GSK), agreed on an off-market purchase of approximately £230 million worth of its own shares after Pfizer said t was cutting its stake by around £2.1 billion.
Haleon's buy rating restated after Pfizer cuts down stake
UBS has reiterated its buy rating on Haleon PLC (LSE:HLN, NYSE:HLN) shares after news that former parent company Pfizer Inc (NYSE:PFE, ETR:PFE) further pared down its stake in the FTSE 100-listed Sensodyne and Panadol maker. Haleon, which comprises the former consumer divisions of Pfizer and GSK PLC (LSE:GSK, NYSE:GSK), agreed on an off-market purchase of approximately £230 million worth of its own shares after Pfizer said t was cutting its stake by around £2.1 billion.
10/01 02:32 EST - proactiveinvestors.co.uk
Haleon buys back some shares as Pfizer sells down stake
Haleon PLC (LSE:HLN, NYSE:HLN) said it has agreed to buy £230 million of its own shares from former co-parent Pfizer Inc (NYSE:PFE, ETR:PFE), which offloaded almost a $3.3 billion stake in the Sensodyne maker. The FTSE 100 consumer health group said made the purchase at a price of 308p per share.
Haleon buys back some shares as Pfizer sells down stake
Haleon PLC (LSE:HLN, NYSE:HLN) said it has agreed to buy £230 million of its own shares from former co-parent Pfizer Inc (NYSE:PFE, ETR:PFE), which offloaded almost a $3.3 billion stake in the Sensodyne maker. The FTSE 100 consumer health group said made the purchase at a price of 308p per share.
10/01 02:13 EST - reuters.com
Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon
Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.
Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon
Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.
09/30 12:14 EST - reuters.com
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon , a bookrunner said on Monday.
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon , a bookrunner said on Monday.
09/27 05:11 EST - reuters.com
Sensodyne maker Haleon to raise stake in China JV
British consumer healthcare company Haleon said on Friday it has agreed to raise its stake in its Chinese joint venture by 33% for 4.47 billion yuan ($637.35 million), taking its ownership to 88%.
Sensodyne maker Haleon to raise stake in China JV
British consumer healthcare company Haleon said on Friday it has agreed to raise its stake in its Chinese joint venture by 33% for 4.47 billion yuan ($637.35 million), taking its ownership to 88%.
09/16 04:00 EST - globenewswire.com
Haleon Selects PubMatic as Supply Optimisation Partner to Enable More Effective, Sustainable Media Buying
The global healthcare brand gains increased transparency and control by getting closer to the sell-side of the ecosystem The global healthcare brand gains increased transparency and control by getting closer to the sell-side of the ecosystem
Haleon Selects PubMatic as Supply Optimisation Partner to Enable More Effective, Sustainable Media Buying
The global healthcare brand gains increased transparency and control by getting closer to the sell-side of the ecosystem The global healthcare brand gains increased transparency and control by getting closer to the sell-side of the ecosystem
09/12 04:09 EST - proactiveinvestors.co.uk
Haleon lays out pricing for £1bn bond offering
Haleon PLC (LSE:HLN, NYSE:HLN) has unveiled pricing for a near-£1 billion bond offering set to be carried out by its subsidiary this month. Some €750 million (£633 million) worth of Euro medium-term notes to mature in 2028 will be sold with a price of 2.875%, the FTSE 100-listed health firm announced Thursday.
Haleon lays out pricing for £1bn bond offering
Haleon PLC (LSE:HLN, NYSE:HLN) has unveiled pricing for a near-£1 billion bond offering set to be carried out by its subsidiary this month. Some €750 million (£633 million) worth of Euro medium-term notes to mature in 2028 will be sold with a price of 2.875%, the FTSE 100-listed health firm announced Thursday.
09/03 08:15 EST - prnewswire.com
Haleon Announces the Launch of Eroxon®, The First and Only FDA Cleared OTC Gel for Erectile Dysfunction, Available for U.S. Preorder Without a Prescription
Eroxon ® is Haleon's first offering in the sexual health space Clinical studies show Eroxon® is safe and effective in men with ED Eroxon® is available now for Amazon pre-order; available on shelves and online at most major retailers in October 2024 WARREN, N.J. , Sept. 3, 2024 /PRNewswire/ -- Eroxon® , the first-and-only FDA cleared gel available without a prescription for the treatment of erectile dysfunction (ED), is now available for pre-order in the United States through Amazon and will be available at most major retailers in October 2024.
Haleon Announces the Launch of Eroxon®, The First and Only FDA Cleared OTC Gel for Erectile Dysfunction, Available for U.S. Preorder Without a Prescription
Eroxon ® is Haleon's first offering in the sexual health space Clinical studies show Eroxon® is safe and effective in men with ED Eroxon® is available now for Amazon pre-order; available on shelves and online at most major retailers in October 2024 WARREN, N.J. , Sept. 3, 2024 /PRNewswire/ -- Eroxon® , the first-and-only FDA cleared gel available without a prescription for the treatment of erectile dysfunction (ED), is now available for pre-order in the United States through Amazon and will be available at most major retailers in October 2024.
08/06 10:30 EST - seekingalpha.com
Haleon: Defensive Consumer Healthcare Stock As Safe Haven
Haleon is a consumer healthcare company formed from a GSK and Pfizer merger, with a 50% share price increase since trading began. Financial results show strong cash flows, with a net profit of 754M GBP and EPS of 7.90 pence per share in the first half of the year. Investment thesis suggests writing put options due to the high EBITDA multiple, with the potential for decreasing net debt and increasing EBITDA in the future.
Haleon: Defensive Consumer Healthcare Stock As Safe Haven
Haleon is a consumer healthcare company formed from a GSK and Pfizer merger, with a 50% share price increase since trading began. Financial results show strong cash flows, with a net profit of 754M GBP and EPS of 7.90 pence per share in the first half of the year. Investment thesis suggests writing put options due to the high EBITDA multiple, with the potential for decreasing net debt and increasing EBITDA in the future.
08/05 10:16 EST - proactiveinvestors.co.uk
Haleon, Reckitt, Wizz Air: Stocks lifting despite global sell-off
While the FTSE 100 continues to suffer its worst session in recent times, dropping 2.5%, there are a handful of companies which have been able to buck the bearish trend. Out of London's blue chips, only Haleon and Reckitt have been able to lift into the green, up by 0.1% and 0.4% respectively.
Haleon, Reckitt, Wizz Air: Stocks lifting despite global sell-off
While the FTSE 100 continues to suffer its worst session in recent times, dropping 2.5%, there are a handful of companies which have been able to buck the bearish trend. Out of London's blue chips, only Haleon and Reckitt have been able to lift into the green, up by 0.1% and 0.4% respectively.
08/02 09:57 EST - proactiveinvestors.co.uk
Haleon a rare riser on tough day as Deutsche Bank hilts resilience
Haleon PLC (LSE:HLN, NYSE:HLN) interim results showed its resilience and dependability in very tough markets, suggests Deutsche Bank adding it deserves a higher rating. “The stock has been strong into results and the positive margin performance, along with some low season improvement in respiratory sell-out, is supporting the stock.
Haleon a rare riser on tough day as Deutsche Bank hilts resilience
Haleon PLC (LSE:HLN, NYSE:HLN) interim results showed its resilience and dependability in very tough markets, suggests Deutsche Bank adding it deserves a higher rating. “The stock has been strong into results and the positive margin performance, along with some low season improvement in respiratory sell-out, is supporting the stock.
08/02 00:28 EST - seekingalpha.com
Haleon plc (HLN) Q2 2024 Earnings Call Transcript
Haleon plc (NYSE:HLN ) Q2 2024 Earnings Call August 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Investor Relations Brian McNamara - Chief Executive Officer Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Bruno Monteyne - Bernstein Chris Pitcher - Redburn Atlantic David Hayes - Jefferies Rashad Kawan - Morgan Stanley Jeremy Fialko - HSBC Olivier Nicolai - Goldman Sachs Celine Pannuti - JPMorgan Iain Simpson - Barclays Operator Good morning, all. Thank you for joining us for the Haleon 2024 Half Year Results Q&A.
Haleon plc (HLN) Q2 2024 Earnings Call Transcript
Haleon plc (NYSE:HLN ) Q2 2024 Earnings Call August 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Investor Relations Brian McNamara - Chief Executive Officer Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Bruno Monteyne - Bernstein Chris Pitcher - Redburn Atlantic David Hayes - Jefferies Rashad Kawan - Morgan Stanley Jeremy Fialko - HSBC Olivier Nicolai - Goldman Sachs Celine Pannuti - JPMorgan Iain Simpson - Barclays Operator Good morning, all. Thank you for joining us for the Haleon 2024 Half Year Results Q&A.
08/01 03:41 EST - proactiveinvestors.co.uk
Haleon ups profit guidance as power brands deliver
Haleon upped its forecast for profit growth this year after a strong performance from its power brands Sensodyne, parodontax and Centrum in the first six months. The consumer brands giant now expects organic profits to rise by a ‘high single-digit percentage', compared to previous guidance of ‘ahead of' the revenue forecast of 4-6%.
Haleon ups profit guidance as power brands deliver
Haleon upped its forecast for profit growth this year after a strong performance from its power brands Sensodyne, parodontax and Centrum in the first six months. The consumer brands giant now expects organic profits to rise by a ‘high single-digit percentage', compared to previous guidance of ‘ahead of' the revenue forecast of 4-6%.